Biogen, Inc. interim head of R&D Priya Singhal will focus on steering the company's broad pipeline while navigating the post-marketing plans for the controversial Alzheimer's therapy, Aduhelm (aducanumab), amid a firestorm of public scrutiny. She took the leadership role on an interim basis in November, after the unexpected departure of longtime R&D leader Al Sandrock and the botched launch of Aduhelm.
Singhal talked to Scrip about the draft decision by the Centers for Medicare & Medicaid Services (CMS) to restrict coverage...
